Sitemap
- Members Portal
- Archives
- Welcome to Domino Analytics
- Research
-
-
Hashgraph Exchange: A White Paper
-
Citibank's View of Roche's TIGIT
-
The Role of PVRIG in Liver Cancer
-
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
-
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
-
CGEN: 11/7/18 Oppenheimer report
-
Developing combination immunotherapies against cancer that make sense
-
A Market Low?
-
Sentiment Update: January 7 -
Sentiment Update for January 4
-
MedImmune Presentation on Wearable Injectors
-
Sentiment Update for December 1
-
CGEN: November Corporate Presentation
-
UNIS: Griffin Securities recap of Annual General Meeting
-
MiMedix (MDXG): Revenue Model
-
Unilife (UNIS): 1Q'16 results
-
MiMedx (MDXG) vs Osiris (OSIR)
-
Sentiment Update
-
MDXG: White Paper
-
UNIS: Buy Reiterated at Griffin Securities
-
CGEN: 3Q'15 Quarterly Review
-
UNIS: 1Q'16 preliminary results
-
MDXG: 3Q'15 results
-
Uni-Pixel: A Speculative Dark Horse As We Round Out 2015
-
Sentiment Update
-
QUIK: Misses 3Q'15 revenue estimates
-
MiMedx: A Mispriced Growth Stock Poised For Outsized Gains
-
EZCH saga continues... Raging Capital nominates two for BOD
-
CGEN: FPRX/BMY Provides Deal Valuation Comp
-
CGEN: Sept Corp Presentation
-
EZCH: Raging Capital a "NO" vote
-
EZCH Proxy Statement
-
EZCH being acquired by MLNX
-
UNIS: $10 million of additional Orbimed funding
-
CGEN: ADC Program Update
-
MDXG: Qui Tam Complaint Against MiMedx is Fully Dismissed
-
MDXG Analyst Day
-
Bristol-Myers JV licenses immuno-oncology assets from Yale
- Become A Contributor
- High-Impact, Low-Probability Investing
- Media
- Blog
- Home